SCHEMBL649387

SCHEMBL649387

CCCCc1c(Cl)cc(Cl)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
HTT P42858 2/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
MAPK1 P28482 1/20 0.37
NOS2 P35228 1/20 0.37
TLR8 Q9NR97 2/20 0.37
TLR7 Q9NYK1 2/20 0.37
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TYMP P19971 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
PSMB5 P28074 1/20 0.32
NR4A2 P43354 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12661864 0.82 CYP2C19 (0.41) HPGDHTTRAB9ANPC1KMT2A
SCHEMBL29710403 0.82 CYP2C19 (0.41) HPGDHTTRAB9ANPC1KMT2A
SCHEMBL16830030 0.76 KDM4E (0.33) HPGDALDH1A1KDM4ELMNACYP1A2
SCHEMBL31292364 0.76 CYP2C19 (0.33) KDM4ELMNACYP1A2CYP2D6CYP2C9
SCHEMBL30592427 0.76 KDM4E (0.33) HPGDALDH1A1KDM4ELMNACYP1A2
SCHEMBL11844604 0.73 NR4A2 (0.38) HPGDNPSR1HTTRAB9ANPC1
SCHEMBL8106157 0.73 NPC1 (0.43) HPGDNPSR1HTTRAB9ANPC1
SCHEMBL31292178 0.72 DPP4 (0.32) HPGDHTTALDH1A1KDM4ELMNA
SCHEMBL5749827 0.71 RAB9A (0.47) HPGDNPSR1HTTRAB9ANPC1
SCHEMBL1321965 0.71 KMT2A (0.39) HPGDNPSR1HTTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators C3AR1, C5AR1, C5AR2 HPGD 1577/4885NPSR1 223/4885HTT 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.